8-K: VolitionRx Secures $2M in New Funding, Issues Convertible Note & Warrants

VolitionRx Limited has secured an additional $2.0 million in gross funding from Lind Global Asset Management XII LLC through a senior secured convertible promissory note and common stock purchase warrants.

Summary

• VolitionRx Limited entered into an Amended and Restated Securities Purchase Agreement with Lind Global Asset Management XII LLC on January 7, 2026.
• The company will receive $2,000,000 in gross funding.
• In exchange, VolitionRx will issue a Senior Secured Convertible Promissory Note with a principal amount of $2,400,000 (the 2026 Note) and a Common Stock Purchase Warrant for 7,000,350 shares at an exercise price of $0.5714 per share.
• A commitment fee of $70,000 will be deducted from the funding, resulting in net proceeds of $1,930,000.
• The 2026 Note does not accrue interest and will be repaid in 18 consecutive monthly installments of $133,333, beginning six months from the issuance date.
• Monthly payments can be made in cash (1.05x payment amount) or common stock valued at 90% of the average of the five lowest daily volume weighted average prices (VWAPs) during the 20 trading days prior to the payment date.
• The 2026 Note is convertible by Lind at $0.5714 per share, representing an aggregate of 4,200,210 shares based on the initial principal.
• This transaction is in addition to a previous $7,500,000 principal note and warrant for 13,020,834 shares issued to Lind on May 15, 2025.
• The company's obligations under both notes are secured by a first-priority security interest in all of its assets and guarantees from its subsidiaries.
• Issuance of shares is subject to a 4.99% beneficial ownership limitation (increasing to 9.99% under certain conditions) and a 19.99% NYSE American listing cap, requiring stockholder approval for exceeding the latter.

Sentiment

Score: 3

Explanation: The financing terms, including the significant discount embedded in the note, the highly dilutive repayment mechanism, and stringent covenants with a market capitalization trigger, suggest the company is accessing capital under unfavorable conditions. While it provides necessary working capital, the long-term cost and potential for substantial shareholder dilution are significant concerns.

Positives

• Secured an additional $2.0 million in gross funding, providing working capital.
• The convertible note does not accrue interest, reducing immediate cash outflow for interest payments.
• Flexibility to repay the note in cash, shares, or a combination, allowing the company to manage cash flow.

Negatives

• The $2.4 million principal amount of the note for $2.0 million gross funding implies a 20% discount/premium built into the principal, effectively a high cost of capital.
• A $70,000 commitment fee further reduces net proceeds to $1.93 million.
• The repayment share price is set at 90% of the average of the five lowest daily VWAPs during the 20 trading days prior to payment, which is highly dilutive if the stock price declines.
• Extensive list of Events of Default, including market capitalization falling below $22.5 million for 10 consecutive trading days, which could trigger immediate repayment at 120% of outstanding principal.
• Negative covenants restrict certain corporate actions like distributions, stock repurchases, and certain types of borrowing or asset sales without Lind's consent.
• The company is required to seek stockholder approval for a reverse stock split targeting a $2.00 post-split price by March 31, 2026, and may be compelled to effect it if the stock falls below $0.20.
• The note is senior secured, giving Lind a first-priority claim on all company assets.
• The NYSE 19.99% Cap requires stockholder approval for significant share issuance, and failure to obtain it allows Lind to demand cash repayment.

Risks

• Dilution Risk: The repayment mechanism (90% of 5 lowest VWAPs) and conversion price ($0.5714) can lead to significant dilution if the stock price falls.
• Market Capitalization Risk: An Event of Default is triggered if the company's market capitalization falls below $22.5 million for 10 consecutive trading days, potentially accelerating repayment at a premium (120% of principal).
• Liquidity Risk: Events of Default can lead to immediate acceleration of the entire outstanding principal (120% or 110%), potentially straining the company's cash reserves.
• Operational Restrictions: Negative covenants limit the company's flexibility in capital allocation (e.g., distributions, stock repurchases, certain borrowings, asset sales).
• Shareholder Approval Risk: Failure to obtain stockholder approval for issuing shares beyond the NYSE 19.99% cap could force cash repayment of the note.
• Reverse Stock Split Risk: The requirement to seek approval for a reverse stock split and potential compulsion to execute it could be perceived negatively by the market or impact trading liquidity.
• Security Interest: The first-priority security interest on all assets and subsidiary guarantees means Lind has a strong claim in case of financial distress.
• Tax Treatment: The note is not intended to be treated as indebtedness for U.S. federal income tax purposes, which could have implications for both parties depending on how it's ultimately treated by tax authorities.

Future Outlook

The company expects to use the proceeds from this financing for working capital purposes. It also plans to hold a stockholder meeting by March 31, 2026, to seek approval for a reverse stock split targeting a post-split trade price of at least $2.00 per share. The company is committed to filing a registration statement within 30 days of closing to cover the resale of shares issued to Lind.

Management Comments

• Volition is a multi-national company focused on advancing the science of epigenetics.
• Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
• Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

Industry Context

VolitionRx operates in the epigenetics industry, focusing on developing and commercializing blood tests for early detection and monitoring of diseases like cancers and conditions associated with NETosis (e.g., sepsis). This financing provides additional capital to support its research and development activities, which are primarily based in Belgium, and its broader commercialization efforts. The company's mission aligns with a growing trend in healthcare towards non-invasive diagnostics and personalized medicine, aiming to improve patient outcomes through earlier intervention.

Comparison to Industry Standards

• The terms of this financing, particularly the significant discount embedded in the note principal ($2.4M for $2.0M funding) and the highly dilutive repayment share price mechanism (90% of 5 lowest VWAPs), are generally considered aggressive and unfavorable for the issuer compared to traditional debt or equity financing.
• The senior secured nature of the note and the extensive list of events of default, including a market capitalization trigger, are common in distressed or high-risk financing scenarios, but less so for companies with strong financial health or access to less restrictive capital.
• The requirement for a reverse stock split to maintain listing compliance or improve stock price perception is a common strategy for micro-cap companies facing delisting risks, but it often signals underlying challenges rather than robust growth.

Corporate Governance

Stakeholder Impact

• Shareholders: Significant potential for dilution due to the convertible note and warrant terms, especially the variable repayment share price. The reverse stock split proposal could also impact shareholder perception and liquidity.
• Creditors: Lind Global Asset Management XII LLC benefits from a first-priority security interest in all company assets and subsidiary guarantees, enhancing its position as a creditor.
• Employees/Management: The financing provides working capital, which supports ongoing operations and potentially job security, but stringent covenants and default triggers add pressure on management performance.

Next Steps

• VolitionRx to receive $2,000,000 in funding from Lind within ten business days of January 7, 2026, subject to closing conditions.
• VolitionRx to file a registration statement within 30 days of closing to register for resale all Note Shares and Warrant Shares issued to Lind.
• VolitionRx to begin monthly repayments of the 2026 Note ($133,333) six months from the issuance date for 18 consecutive months.
• VolitionRx to hold a special meeting of stockholders on or before March 31, 2026, to obtain approval for a reverse stock split.
• If stockholder approval for the NYSE 19.99% Cap is not obtained, Lind may request cash repayment of the remaining note balance.

Key Dates

Recommendation

The terms of this financing are highly unfavorable for existing shareholders, indicating potential financial distress or limited access to less dilutive capital. The significant discount embedded in the note, the highly dilutive repayment mechanism tied to low VWAPs, and the stringent covenants with a market capitalization trigger create substantial downside risk. The need for a reverse stock split further signals underlying issues. While the funding provides short-term liquidity, the long-term cost of capital and potential for severe dilution make the stock a 'sell' for seasoned investors concerned about shareholder value preservation.

Keywords

VolitionRx, VNRX, Lind Global Asset Management, Convertible Note, Warrant, Secured Financing, Equity Financing, Dilution, SEC Filing, 8-K, Epigenetics, Biotechnology, Capital Raise, Debt Financing, Stockholder Approval, Reverse Stock Split